Funding

#Bioinformatics #Enedra Therapeutics #Funding #Oncology #Precision medicine #Start-ups

Enedra secures financing for precision cancer therapies

Enedra Therapeutics has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers.  The financing round was supported by KU Leuven’s Centre for Drug Design and Discovery (CD3), o2h Ventures, and follow-on… Read More

#Business & Investment #News #Start-up Zone

#AACR #Cancer research #Funding #Oncology

New $15 million cancer research grant launched at AACR

The AACR Trailblazer Cancer Research Grant Program, which was launched at the Annual Meeting Opening Ceremony, will award $15 million over three years.  It is designed for early-stage and mid-career investigators to support meritorious and promising cancer research.  “AACR has been a proud funder of… Read More

#Cancer Research #News

#BioMed X #Biomedical research #Funding #National Institutes of Health (NIH) #United States

XBridge Program launches for researchers impacted by NIH cuts

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, has announced the launch of its XBridge Program, a fast-track initiative designed to support US-based biomedical researchers impacted by the current NIH funding gaps, hiring freezes, and grant terminations.   The programme is a kind of matchmaking… Read More

#News

Downing Street, London, UK
#Funding #Life sciences #Research and development #UK #UK government

UK government commits £13.9 billion for R&D funding

The UK Department for Science, Innovation and Technology (DSIT) has set out how it will allocate £13.9 ($17.9) billion in funding for transformational research and development in the next year in areas like life sciences, green energy, engineering and beyond.   UK Research and Innovation (UKRI) – the… Read More

#News #Trending News

#Funding #National Institutes of Health (NIH) #Politics #Research and development

From the Editor: Science under threat

It seems rather obvious, and somewhat unfair to DDW’s readers – considering how much he has been in the news recently – to talk more about President Donald Trump and specifically his decision to cut billions of dollars in funding to the National Institutes of Health (NIH).  The decision comes on… Read More

#Exclusive Content #Opinion

#Biotech #Business #China #Drug discovery #Funding

How has the biotech international market planning evolved

Sam Tomlinson, Vice President of Global Drug Safety at Arriello unpacks North America/EU research which compares today’s commercialisation strategies with those of five years ago.   As biotechs around the world look to new territories including emerging markets for their next returns, many are encountering unexpected hurdles. Too often, there is a… Read More

#Exclusive Content

#BioInnovation Institute #Biologics / Biotechnology #Biotech hubs #Drug discovery #Funding #Investment #Life sciences #Market reporting #Start-ups #United States

New podcast: Global epicentres of drug discovery innovation

This is the latest episode of the free DDW narrated podcast, titled “Where are the global epicentres of drug discovery innovation?”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Where are the hottest drug discovery hubs in the… Read More

#News

Bacteria Citrobacter
#antibiotic #Antimicrobials #Artificial intelligence (AI) #Funding #Oxford Drug Design #Urinary

Oxford Drug Design awarded £1m to progress uUTI treatment

Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy).  In the UK, there were over 1.8 million hospital admissions involving UTIs between 2018-19 and 2022-23, with the condition being responsible for… Read More

#Business & Investment #News

#Antimicrobial resistance (AMR) #Bacteria #Funding #Gram-negative bacteria #Infex Therapeutics

£1m grant for drug targeting multi-drug-resistant bacteria

Infex Therapeutics, in collaboration with Justus-Liebig-University Giessen (JLU), Germany, has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy).  The company plans to develop a first-in-class BamA inhibitor targeting multi-drug-resistant (MDR) Gram-negative pathogens.  BamA inhibitors are an entirely new class of antimicrobial drug designed to target… Read More

#Business & Investment #News

National Institutes of Health
#Funding #National Institutes of Health (NIH) #Politics

NIH cuts billions in funding for medical research

The Trump administration in the US has announced plans to cut billions of dollars in funding for costs related to medical research funding in universities, hospitals and other scientific institutions.  These grants include payments for “indirect costs,” defined as “facilities” and “administration”, which cost up to $9… Read More

#News #Trending News

Bacteria in Petri dishes
#Antibiotics #Antimicrobial resistance (AMR) #Cystic fibrosis #Funding #Glox Therapeutics #LifeArc

Glox awarded share of £3m cystic fibrosis funding

Glox Therapeutics has been awarded a share of the £3 ($3.6) million funding from the Collaborative Discovery Programme (CDP), launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from LifeArc.   Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its precision… Read More

#Business & Investment #News

Blood cancer
#Blood cancer #Funding #Haematology #Leukaemia #Washington University School of Medicine

$10.8 million grant supports leukaemia drug discovery projects

Washington University School of Medicine in St Louis has been awarded a five-year $10.8 million grant to further its programmes in leukaemia and other blood cancers.  The grant, from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), renews funding for the Specialized Program of Research Excellence… Read More

#Business & Investment #News

#Big pharma #Funding #Patient groups #Pharmaceutical industry #University of Bath

Patient groups influenced by drug company funding, study finds

Action is needed to safeguard the independence of patient organisations and charities, according to the findings of a new study.  The study by the University of Bath, UK, Lund University, Sweden and Kozminski University, Poland, concludes that patient organisations and charities across Europe are at risk of aligning their interests… Read More

#Business & Investment #News

mRNA
#Circio Holding #circular RNAs #DNA #Funding #mRNA #Norway #RNA #Viral vectors

NOK 10.7 million supports circular mRNA technology

Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology. The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and… Read More

#News

IgE antibodies
#Antibodies #Bifunctional medicine #Cancer research #Funding #Investment #Ottimo Pharma

Bifunctional medicines to extend the lives of cancer patients

Ottimo Pharma has completed a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets. The round was led… Read More

#Business & Investment #Cancer Research #Editor's Choice #News